About Zyl Therapeutics
Zyl Therapeutics is a company based in Greenville (United States) founded in 2017 by Scott Pancoast.. Zyl Therapeutics has raised $9.43 million across 6 funding rounds from investors including NIH, SCRA and NIH SBIR/STTR. Zyl Therapeutics offers products and services including Z-pods. Zyl Therapeutics operates in a competitive market with competitors including PanTher Therapeutics, PolyPid, Sirnaomics, Ensysce and Arcturus Therapeutics, among others.
- Headquarter Greenville, United States
- Founders Scott Pancoast
-
Sectors
TechnologyHealthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$9.43 M (USD)
in 6 rounds
-
Latest Funding Round
$294 K (USD), Grant
May 31, 2023
-
Investors
NIH
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zyl Therapeutics
Zyl Therapeutics offers a comprehensive portfolio of products and services, including Z-pods. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for innovative and sustained topical drug delivery.
Unlock access to complete
Funding Insights of Zyl Therapeutics
Zyl Therapeutics has successfully raised a total of $9.43M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $294 thousand completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $294,000
-
First Round
First Round
(01 Jun 2018)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Grant - Zyl Therapeutics | Valuation |
investors |
|
| Sep, 2022 | Amount | Grant - Zyl Therapeutics | Valuation |
investors |
|
| Jun, 2022 | Amount | Series B - Zyl Therapeutics | Valuation | VentureSouth , New York Angels |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Zyl Therapeutics
Zyl Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, SCRA and NIH SBIR/STTR. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage ventures in the Southeast are supported by VentureSouth.
|
Founded Year | Domain | Location | |
|
Early-stage technology startups are funded by New York Angels network.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Zyl Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Zyl Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Zyl Therapeutics Comparisons
Competitors of Zyl Therapeutics
Zyl Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PanTher Therapeutics, PolyPid, Sirnaomics, Ensysce and Arcturus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API)
|
|
| domain | founded_year | HQ Location |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| domain | founded_year | HQ Location |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| domain | founded_year | HQ Location |
Erythrocyte encapsulation systems for drug delivery are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Zyl Therapeutics
Frequently Asked Questions about Zyl Therapeutics
When was Zyl Therapeutics founded?
Zyl Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Zyl Therapeutics located?
Zyl Therapeutics is headquartered in Greenville, United States.
Who is the current CEO of Zyl Therapeutics?
Scott Pancoast is the current CEO of Zyl Therapeutics. They have also founded this company.
Is Zyl Therapeutics a funded company?
Zyl Therapeutics is a funded company, having raised a total of $9.43M across 6 funding rounds to date. The company's 1st funding round was a Series B of $5.23M, raised on Jun 01, 2018.
What does Zyl Therapeutics do?
Zyl Therapeutics was founded in 2017 and is based in Greenville, United States. A patented drug delivery system known as Nanopods, derived from hydrogels, is developed by the company for topical applications. Payloads including nitric oxide, curcumin, cannabis, siRNA, iron, and melanin can be delivered through this system. Operations focus on biotechnology and pharmaceutical sectors, with emphasis on nanoparticle innovations for skin-based treatments.
Who are the top competitors of Zyl Therapeutics?
Zyl Therapeutics's top competitors include PanTher Therapeutics, Sirnaomics and Arcturus Therapeutics.
What products or services does Zyl Therapeutics offer?
Zyl Therapeutics offers Z-pods.
Who are Zyl Therapeutics's investors?
Zyl Therapeutics has 10 investors. Key investors include NIH, SCRA, NIH SBIR/STTR, VentureSouth, and New York Angels.